drugset / Trial / NCT05224336

Psilocybin-assisted Therapy for Phantom Limb Pain

NCT05224336

Phase 1 Completed 10 enrolled University of California, San Diego
RandomizedParallel-groupTriple-blindTreatment

Summary

This double-blind placebo-controlled pilot study seeks to investigate whether psilocybin can be safely administered to people with chronic phantom limb pain (PLP) in a supportive setting with close follow-up, and its effects on pain symptoms and other moods, attitudes, and behaviors. The investigators' primary hypotheses are that psilocybin is safe to administer in people with PLP and that it will reduce scores on measures of pain. The investigators will also assess a number of secondary measures related to the behavioral and neural responses to pain after psilocybin treatment.

Timeline

Start
2022-10-03
Primary completion
2024-03-07
Completion
2024-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg Oral

Indications

No indication recorded.